'Gimme five': future challenges in multiple sclerosis. ECTRIMS Lecture 2009.
This article is based on the ECTRIMS lecture given at the 25( th) ECTRIMS meeting which was held in Dusseldorf, Germany, from 9 to 12 September 2009. Five challenges have been identified: (1) safeguarding the principles of medical ethics; (2) optimizing the risk/benefit ratio; (3) bridging the gap between multiple sclerosis and experimental autoimmune encephalitis; (4) promoting neuroprotection and repair; and (5) tailoring multiple sclerosis therapy to the individual patient. Each of these challenges will be discussed and placed in the context of current research into the pathogenesis and treatment of multiple sclerosis.
Hohlfeld
Reinhard
R
Institute of Clinical Neuroimmunology, Ludwig Maximilians University of Munich, München, Germany. reinhard.hohlfeld@med.uni-muenchen.de
D000818:Animals; D004195:Disease Models, Animal; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000235:genetics / Q000628:therapy; D004992:Ethics, Medical; D005060:Europe; D005818:Genetic Engineering; D006801:Humans; D009103:Multiple Sclerosis / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D009420:Nervous System / Q000473:pathology; D018696:Neuroprotective Agents / Q000627:therapeutic use; D057285:Precision Medicine; D040901:Proteomics; D018570:Risk Assessment
D018696:Neuroprotective Agents